New Data on CARVYKTI® for Multiple Myeloma Patients Unveiled at Major Cancer Conferences, US

Date:

Updated: [falahcoin_post_modified_date]

Legend Biotech Corporation announced that new and updated data from the CARTITUDE clinical development program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association?s (EHA) Hybrid Congress. Data from Cohort D of the Phase 2 CARTITUDE-2 study investigating a single infusion of CARVYKTI® with or without lenalidomide maintenance in patients who achieved less than complete response after autologous stem cell transplant (ASCT) frontline therapy will be presented for the first time in an oral presentation at ASCO and in an encore oral presentation at EHA. Data from the subgroup analysis of the Phase 3 CARTITUDE-4 study of CARVYKTI® versus two standard therapies in patients with functional high-risk multiple myeloma after one prior line of treatment will be presented in an oral presentation at ASCO.

Additionally, the results of the CARTITUDE-4 subgroup analysis by cytogenetic risk will be shared at EHA in a poster session. INCREASED EARLY MORTALITY – In CARTITUDE-4, a (1:1) randomized controlled trial, there was a numerically higher percentage of early deaths in patients randomized to the CARVYKTI® treatment arm compared to the control arm. Among patients with deaths occurring within the first 10 months from randomization, a greater proportion (29/208; 14%) occurred in the CARVYKTI® arm compared to (25/211; 12%) in the control arm.

Of the 29 deaths that occurred in the CARVYKTI® arm within the first 10 months of randomization, 10 deaths occurred prior to CARVYKTI® infusion, and 19 deaths occurred after CARVYKTI® infusion. Of the 10 deaths that occurred prior to CARVYKTI® infusion, all occurred due to disease progression, and none occurred due to adverse events. Of the 19 deaths that occurred after CARVYKTI® infusion, 3 occurred due to disease progression, and 16 occurred due to adverse events.

The most common adverse events were due to infection (n=12). CYTOKINE RELEASE SYNDROME (CRS),including fatal or life-threatening reactions, occurred following treatment with CARVYKTI®. Among patients receiving CARVYKTI® for RRMM in the CARTITUDE-1 & 4 studies (N=285), CRS occurred in 84% (238/285), including = Grade 3 CRS (ASCT 2019) in 4% (11/285) of patients.

Median time to onset of CRS, any grade, was 7 days (range: 1 to 23 days). CRS resolved in 82% with a median duration of 4 days (range: 1 to 97 days). The most common manifestations of CRS in all patients combined (= 10%) included fever (84%), hypotension (29%) and aspartate aminotransferase increased (11%).

[single_post_faqs]
Rohan Desai
Rohan Desai
Rohan Desai is a health-conscious author at The Reportify who keeps you informed about important topics related to health and wellness. With a focus on promoting well-being, Rohan shares valuable insights, tips, and news in the Health category. He can be reached at rohan@thereportify.com for any inquiries or further information.

Share post:

Subscribe

Popular

More like this
Related

Revolutionary Small Business Exchange Network Connects Sellers and Buyers

Revolutionary SBEN connects small business sellers and buyers, transforming the way businesses are bought and sold in the U.S.

District 1 Commissioner Race Results Delayed by Recounts & Ballot Reviews, US

District 1 Commissioner Race in Orange County faces delays with recounts and ballot reviews. Find out who will come out on top in this close election.

Fed Minutes Hint at Potential Rate Cut in September amid Economic Uncertainty, US

Federal Reserve minutes suggest potential rate cut in September amid economic uncertainty. Find out more about the upcoming policy decisions.

Baltimore Orioles Host First-Ever ‘Faith Night’ with Players Sharing Testimonies, US

Experience the powerful testimonies of Baltimore Orioles players on their first-ever 'Faith Night.' Hear how their faith impacts their lives on and off the field.